vs
Apellis Pharmaceuticals, Inc.（APLS）与Utz Brands, Inc.（UTZ）财务数据对比。点击上方公司名可切换其他公司
Utz Brands, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$341.0M vs $199.9M），Utz Brands, Inc.净利率更高（0.7% vs -29.5%，领先30.2%），Utz Brands, Inc.同比增速更快（-3.1% vs -5.9%），Utz Brands, Inc.自由现金流更多（$16.5M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.5%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Utz Brands, Inc.常简称为Utz，是总部位于美国宾夕法尼亚州汉诺威的休闲食品企业。该公司主打生产薯片、碱水脆饼等多种休闲食品，大部分产品以旗下品牌矩阵发售，同时也为仓储式会员店和批发商供应休闲零食。
APLS vs UTZ — 直观对比
营收规模更大
UTZ
是对方的1.7倍
$199.9M
营收增速更快
UTZ
高出2.8%
-5.9%
净利率更高
UTZ
高出30.2%
-29.5%
自由现金流更多
UTZ
多$30.8M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.5%
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $341.0M |
| 净利润 | $-59.0M | $2.3M |
| 毛利率 | — | 25.5% |
| 营业利润率 | -25.6% | 2.1% |
| 净利率 | -29.5% | 0.7% |
| 营收同比 | -5.9% | -3.1% |
| 净利润同比 | -62.2% | 108.3% |
| 每股收益（稀释后） | $-0.40 | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSUTZ
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | — | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $341.0M | ||
| Q3 24 | $196.8M | $365.5M | ||
| Q2 24 | $199.7M | $356.2M | ||
| Q1 24 | $172.3M | $346.5M |
净利润APLSUTZ
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $2.3M | ||
| Q3 24 | $-57.4M | $-2.2M | ||
| Q2 24 | $-37.7M | $19.8M | ||
| Q1 24 | $-66.4M | $-4.0M |
毛利率APLSUTZ
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 25.5% | ||
| Q3 24 | — | 26.9% | ||
| Q2 24 | — | 26.7% | ||
| Q1 24 | — | 25.5% |
营业利润率APLSUTZ
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | 2.1% | ||
| Q3 24 | -24.0% | 5.3% | ||
| Q2 24 | -14.7% | 6.3% | ||
| Q1 24 | -36.0% | 2.8% |
净利率APLSUTZ
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | 0.7% | ||
| Q3 24 | -29.2% | -0.6% | ||
| Q2 24 | -18.9% | 5.6% | ||
| Q1 24 | -38.5% | -1.2% |
每股收益（稀释后）APLSUTZ
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $0.04 | ||
| Q3 24 | $-0.46 | $-0.03 | ||
| Q2 24 | $-0.30 | $0.23 | ||
| Q1 24 | $-0.54 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $56.1M |
| 总债务越低越好 | — | $768.6M |
| 股东权益账面价值 | $370.1M | $696.9M |
| 总资产 | $1.1B | $2.7B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资APLSUTZ
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $56.1M | ||
| Q3 24 | $396.9M | $64.9M | ||
| Q2 24 | $360.1M | $66.6M | ||
| Q1 24 | $325.9M | $47.0M |
总债务APLSUTZ
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $768.6M | ||
| Q3 24 | — | $780.8M | ||
| Q2 24 | — | $797.6M | ||
| Q1 24 | $93.1M | $756.9M |
股东权益APLSUTZ
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $696.9M | ||
| Q3 24 | $237.1M | $685.7M | ||
| Q2 24 | $264.3M | $686.0M | ||
| Q1 24 | $266.7M | $671.1M |
总资产APLSUTZ
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $2.7B | ||
| Q3 24 | $901.9M | $2.6B | ||
| Q2 24 | $904.5M | $2.7B | ||
| Q1 24 | $831.9M | $2.6B |
负债/权益比APLSUTZ
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.10× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.16× | ||
| Q1 24 | 0.35× | 1.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $54.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $16.5M |
| 自由现金流率自由现金流/营收 | -7.1% | 4.8% |
| 资本支出强度资本支出/营收 | 0.1% | 11.1% |
| 现金转化率经营现金流/净利润 | — | 23.67× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $7.6M |
8季度趋势，按日历期对齐
经营现金流APLSUTZ
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $54.2M | ||
| Q3 24 | $34.1M | $52.2M | ||
| Q2 24 | $-8.3M | $8.9M | ||
| Q1 24 | $-133.0M | $-9.1M |
自由现金流APLSUTZ
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $16.5M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | $-8.4M | $-15.3M | ||
| Q1 24 | $-133.3M | $-22.7M |
自由现金流率APLSUTZ
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 4.8% | ||
| Q3 24 | — | 8.0% | ||
| Q2 24 | -4.2% | -4.3% | ||
| Q1 24 | -77.3% | -6.5% |
资本支出强度APLSUTZ
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 11.1% | ||
| Q3 24 | 0.0% | 6.3% | ||
| Q2 24 | 0.0% | 6.8% | ||
| Q1 24 | 0.2% | 3.9% |
现金转化率APLSUTZ
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.45× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UTZ
暂无分部数据
